12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aldoxorubicin: Additional Phase II data

Additional data from an open-label, international Phase IIb trial in 123 patients with STS showed that first-line treatment with 350 mg/m 2 IV aldoxorubicin on day 1 of each 21-day cycle met the primary endpoint of improving PFS vs. doxorubicin. Specifically, aldoxorubicin improved median PFS as assessed by investigators (8.4 vs. 4.7 months, p=0.0002) and by blinded central laboratory review (5.7 vs. 2.8 months, p=0.018) vs. doxorubicin. On secondary endpoints, aldoxorubicin significantly improved 6-month PFS rates as assessed by investigators (67.1% vs. 36.1%, p=0.005) and by blinded...

Read the full 413 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >